Committing more than $6 billion in potential milestone payments, Sanofi said it will partner with IGM Biosciences to create, develop, manufacture, and commercialize six immunoglobulin M (IgM) antibody ...
IGM Biosciences, Inc. (IGMS) has built a substantial pipeline full of a few clinical candidates that have been progressing in the clinic. One such drug would be imvotamab, which is a CD20 X CD3 ...
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...
MOUNTAIN VIEW, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results